Dr. Jayant J. Khandare is a globally recognized cancer innovator and entrepreneur with more than two decades of experience at the intersection of chemical engineering, biomaterials, cancer biology, and translational oncology. He is the scientific architect behind multiple breakthrough platforms spanning cancer diagnostics, circulating tumor cell (CTC) technologies, and therapeutic intervention systems, many of which have progressed from concept to clinical and commercial validation.

Dr. Khandare has authored over 150+ peer-reviewed scientific publications and is a named inventor on 25+ U.S. patents, reflecting a sustained track record of converting deep science into protectable, scalable intellectual property. His innovations form the foundation of several clinically relevant oncology platforms, including OncoDiscover® (CTC detection and enumeration) and OncoMetastat® (extracorporeal CTC filtration for metastasis mitigation)—technologies designed to address the most critical unmet need in cancer: the prevention and control of metastasis.

Internationally trained, Dr. Khandare has held advanced research appointments in the United States and Germany, including postdoctoral work at Wayne State University, Rutgers University, and Freie Universität Berlin, with a strong focus on targeted drug delivery, macromolecular therapeutics, and cancer cell–material interactions. He is an Alexander von Humboldt Foundation Experienced Researcher and a Fellow of the Royal Society of Chemistry (UK), honors reserved for scientists with sustained international impact.

As a scientific founder and operator, Dr. Khandare brings a rare combination of visionary platform thinking and execution discipline. He has successfully built technologies across the full innovation lifecycle—from fundamental materials science and device engineering to translational studies, regulatory pathways, and clinical adoption. Under his leadership, Actorius’ platforms have generated extensive clinical evidence, international publications (ASCO, AACR, ESMO, ISLB), and a growing global IP estate.

Dr. Khandare’s entrepreneurial mission is clear and consistent: to create first-in-class technologies that redefine how cancer is detected, monitored, and treated, with a particular focus on systemic disease biology rather than organ-limited paradigms. His work positions Actorius at the forefront of a new category in oncology—interventional cancer diagnostics and therapeutics.